In this study, the concentration of the four metabolites and established AD biomarker, p-tau, in the CSF were weakly correlated, although another established AD biomarker, Aβ42, did not show similarly significant results (Figs. 3, 4). This evidence concerns the gene MAPT and Alzheimer disease.